Skip to content
OpenCapital
Get started

Geron GERN Cash & Equivalents

Cash & Equivalents at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$9.57B-12.0%
Incyte logo
IncyteINCY
$3.46B+78.2%
Immunome logo
ImmunomeIMNM
$582.69M+126%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$130.89M-15.0%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$201M+4.7%
Celcuity logo
CelcuityCELC
$145.19M+781%

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$888.51M-7.6%
Enterprise value$973.78M-5.3%
P/S4.7×-174×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:CashEquivalentsAtCarryingValue.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's cash & equivalents?
Geron (GERN) reported cash & equivalents of $48.72M in Q1 2026.
How has Geron's cash & equivalents changed year-over-year?
Geron's cash & equivalents decreased by 12.2% year-over-year, from $55.51M to $48.72M.
What is the long-term trend for Geron's cash & equivalents?
Over 5 years (2020 to 2025), Geron's cash & equivalents has grown at a 40.3% compound annual growth rate (CAGR), from $9.93M to $53.93M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.